Febrile neutropeniaChemotherapyBreast cancerNon-Hodgkin's lymphomaPancreatic cancerConsiderable evidence exists concerning the risk of febrile neutropenia (FN) associated with well-established, older chemotherapy regimens. Little is known, however, about the risks associated with many regimens that were ...
Statistical methods The risk of developing at least 1 episode of neutropenia typically increases over time during treatment, and a time-dependent bias may arise, since patients who de- velop neutropenia must have survived until the time they developed neutropenia. As in our previous analysis [4],...
some cases.17 The development of prophylactic granulocyte colony stimulating factor (G-CSF) shortens the duration of neutropenia and reduces related infections.18 It also reduces the incidence and severity of neutropenia in high-risk patients.19 But G-CSF is not routinely prescribed to all patients...
We analyzed data from 271 patients who had small cell lung cancer, non-Hodgkin's lymphoma, head and neck cancer, or breast cancer; 63.8 % of the patients had advanced cancer, and 77.5 % received chemotherapy regimens with high risk of febrile neutropenia. In the first cycle, 18.8 % of ...
So can preoperative chemotherapy alone be given in full systemic doses, and RT omitted for patients with a high risk of systemic relapse? This systematic review aims to examine current evidence regarding the potential role of NACT alone or as either induction or consolidation in addition to RT ...
This condition is one of the main toxicities in patients receiving common chemotherapy regimens. It is responsible for a significant amount of morbidity and a significant risk of mortality because of its associated increased risk of infection12. Yet, the monitoring of severe neutropenia is currently ...
6. ABVD-Related Neutropenia and HIV Patients Patients with human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) are at an increased risk of developing HL. Though not an AIDS-defining illness, the incidence of HL is high in these patients and even higher in...
Chemotherapy administration is an error-prone, high-risk process [1, 2]. The reasons are well known. The number and complexity of chemotherapy regimens are increasing steadily; most cytotoxic drugs have a narrow therapeutic range; dose adjustments are often needed; cancer patients are particularly ...
To ensure the safety of NAT, pegylated granulocyte colony-stimulating factor was prophylactically used for patients with intermediate or high-risk of febrile neutropenia according to the guidelines of CSCO. However, 23.5% of patients still developed leukopenia. The most common AE was anemia (62.0%)...
Additional file6: Figure S5 summarizes the odds ratios of adverse outcomes in patients treated with either GEM/NAB-P or FOLFIRINOX, the top-ranked regimens in this analysis. Some important findings include the significantly increased odds for grade 3–4 neutropenia observed in patients treated with...